Efficacy of dupilumab in atopic dermatitis with prurigo: a real-life study
Clicks: 14
ID: 322566
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
3.9
/100
14 views
7 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #38 of 183 articles by views in clinical and experimental dermatology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 183 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
This study assesses the real-world efficacy of dupilumab in patients with atopic dermatitis presenting with prurigo nodularis, compared to those without. In a retrospective cohort of 101 patients followed for 12 months, we show that dupilumab is effective in both groups, although patients with prurigo experience a delayed clinical response. Our findings support maintaining treatment beyond four months in this phenotype and highlight the need for further comparative studies with emerging therapies.
| Reference Key |
openalex_W7171181428
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Amandine Beaune, Aude Clément, Céline Lambert, M. Bachelerie, M. D’Incan, Jacques Rouanet, Justine Pasteur |
| Journal | clinical and experimental dermatology |
| Year | 2026 |
| DOI |
10.1093/ced/llag331
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.